Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT07437950)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial): a one-minute explainerNCT074379501 min

Biospecimen Collection trial for Acute Myeloid Leukemia (NCT07437950). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for people aged 60 or older with newly diagnosed acute myeloid leukemia, unsuitable for intensive therapy and assigned through myeloMATCH. Acute promyelocytic leukemia and FLT3 or TP53 mutations are excluded.

The idea: compare 14 versus 28 days of oral venetoclax per 28-day cycle, alongside five days of oral decitabine/cedazuridine. Venetoclax blocks BCL-2 survival signals. Decitabine attacks abnormal marrow cells; cedazuridine slows its breakdown. Researchers compare deep remissions after six months.

This phase 2 study plans 126 patients. Uma Borate leads; the record lists 49 recruiting US locations.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.